Tinostamustine Dosing by Platelet Count for Lymphoma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapy treatments for lymphoma and T-cell malignant diseases often cause severe adverse effects due to the difficulty in targeting cancer cells specifically, and there is a need for more effective treatments that can deliver the highest possible dose without exceeding the patient's tolerance limits.
Innovation Solution
Tinostamustine is administered at tailored doses based on a patient's platelet count, with higher doses for higher platelet counts and lower doses for lower platelet counts to maximize therapeutic benefit while minimizing adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is administered at high doses to maximize therapeutic benefit, then treatment efficacy is improved, but adverse effects increase due to inability to target cancer cells specifically
Solution Approach 1:
The patent applies parameter changes by adjusting the chemotherapy dose based on the patient's platelet count parameter. Patients with higher platelet counts receive higher doses (e.g., 100 mg/m²) while those with lower platelet counts receive lower doses (e.g., 50 mg/m²), optimizing the balance between treatment efficacy and toxicity for each individual patient
2Productivity
If chemotherapy dose is increased to overcome resistance and improve survival rates, then therapeutic benefit is maximized, but patient tolerance is exceeded leading to severe toxicity
Solution Approach 1:
The patent implements dynamics by making the chemotherapy dose adjustable and adaptable based on the patient's platelet count. The dose is not fixed but dynamically determined according to individual patient parameters, allowing optimization of survival benefit while staying within tolerance limits
Solution Approach 2:
The patent changes the dose parameter based on the platelet count parameter, establishing a relationship where higher platelet counts enable higher doses for improved survival, while lower platelet counts require dose reduction to avoid excessive toxicity
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The invention relates to tinostamustine for use in the treatment of lymphoma or a T-cell malignant disease. Tinostamustine may cause side effects when administered to a patient, and it is desirable to minimise such effects. T he present invention defines an improved treatment, wherein the dose of tinostamustine administered is varied based on the patient's platelet count.